Cargando…

Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine

This study investigated the frequency of adverse reactions to COVID-19 vaccines in Japan and the impact of first-dose adverse reactions on second-dose adverse reactions. Individuals who received an mRNA COVID-19 vaccine at our center in March or April 2021 were included. Data were collected using qu...

Descripción completa

Detalles Bibliográficos
Autores principales: Goda, Ken, Kenzaka, Tsuneaki, Yahata, Shinsuke, Okayama, Masanobu, Nishisaki, Hogara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416330/
https://www.ncbi.nlm.nih.gov/pubmed/36016120
http://dx.doi.org/10.3390/vaccines10081232
_version_ 1784776453774114816
author Goda, Ken
Kenzaka, Tsuneaki
Yahata, Shinsuke
Okayama, Masanobu
Nishisaki, Hogara
author_facet Goda, Ken
Kenzaka, Tsuneaki
Yahata, Shinsuke
Okayama, Masanobu
Nishisaki, Hogara
author_sort Goda, Ken
collection PubMed
description This study investigated the frequency of adverse reactions to COVID-19 vaccines in Japan and the impact of first-dose adverse reactions on second-dose adverse reactions. Individuals who received an mRNA COVID-19 vaccine at our center in March or April 2021 were included. Data were collected using questionnaires. The main factors were age (<40, 40–59, and >60 years), sex, underlying disease, and first-dose adverse reaction. The primary outcomes were incidence of local and systemic adverse reactions (ARs) attributable to the vaccine. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Among 671 participants, 90% experienced local or systemic ARs. An AR to the first dose was associated with a significantly increased risk of an AR to the second dose (OR: 49.63, 95% CI: 21.96–112.16). ARs were less common among men than among women (OR: 0.36, 95% CI: 0.17–0.76). Local ARs were less common among those aged 60 years or older (OR: 0.35, 95% CI: 0.18–0.66), whereas systemic ARs were more common among those aged under 40 years. Information on ARs to the first dose is important for healthcare providers and recipients when making vaccination decisions.
format Online
Article
Text
id pubmed-9416330
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94163302022-08-27 Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine Goda, Ken Kenzaka, Tsuneaki Yahata, Shinsuke Okayama, Masanobu Nishisaki, Hogara Vaccines (Basel) Article This study investigated the frequency of adverse reactions to COVID-19 vaccines in Japan and the impact of first-dose adverse reactions on second-dose adverse reactions. Individuals who received an mRNA COVID-19 vaccine at our center in March or April 2021 were included. Data were collected using questionnaires. The main factors were age (<40, 40–59, and >60 years), sex, underlying disease, and first-dose adverse reaction. The primary outcomes were incidence of local and systemic adverse reactions (ARs) attributable to the vaccine. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Among 671 participants, 90% experienced local or systemic ARs. An AR to the first dose was associated with a significantly increased risk of an AR to the second dose (OR: 49.63, 95% CI: 21.96–112.16). ARs were less common among men than among women (OR: 0.36, 95% CI: 0.17–0.76). Local ARs were less common among those aged 60 years or older (OR: 0.35, 95% CI: 0.18–0.66), whereas systemic ARs were more common among those aged under 40 years. Information on ARs to the first dose is important for healthcare providers and recipients when making vaccination decisions. MDPI 2022-07-31 /pmc/articles/PMC9416330/ /pubmed/36016120 http://dx.doi.org/10.3390/vaccines10081232 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Goda, Ken
Kenzaka, Tsuneaki
Yahata, Shinsuke
Okayama, Masanobu
Nishisaki, Hogara
Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine
title Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine
title_full Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine
title_fullStr Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine
title_full_unstemmed Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine
title_short Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine
title_sort association between adverse reactions to the first and second doses of covid-19 vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416330/
https://www.ncbi.nlm.nih.gov/pubmed/36016120
http://dx.doi.org/10.3390/vaccines10081232
work_keys_str_mv AT godaken associationbetweenadversereactionstothefirstandseconddosesofcovid19vaccine
AT kenzakatsuneaki associationbetweenadversereactionstothefirstandseconddosesofcovid19vaccine
AT yahatashinsuke associationbetweenadversereactionstothefirstandseconddosesofcovid19vaccine
AT okayamamasanobu associationbetweenadversereactionstothefirstandseconddosesofcovid19vaccine
AT nishisakihogara associationbetweenadversereactionstothefirstandseconddosesofcovid19vaccine